Related Experiment Videos
Serum IgA deficiency induced by prolonged phenytoin treatment
Insights
Epileptic children treated with phenytoin showed lower immunoglobulin A (IgA) and immunoglobulin M (IgM) levels compared to controls. Lower IgA levels correlated with longer phenytoin treatment duration in pediatric epilepsy patients.
Area of Science:
- Immunology
- Pediatric Neurology
- Pharmacology
Background:
- Epilepsy is a common neurological disorder in children.
- Phenytoin is a widely used antiepileptic drug.
- Immunological side effects of antiepileptic drugs are a concern.
Purpose of the Study:
- To evaluate immunological parameters in epileptic children and adolescents treated with phenytoin.
- To compare immunoglobulin levels between patients and healthy controls.
- To investigate the correlation between phenytoin treatment duration and immunoglobulin levels.
Main Methods:
- Longitudinal study design.
- Inclusion of 33 epileptic children and adolescents (4-14 years old) treated with phenytoin.
- Comparison with matched normal controls.
- Measurement of serum IgA and IgM levels.
- Analysis of T lymphocyte subpopulations in a subset of patients.
Main Results:
- Significantly lower serum IgA and IgM levels were observed in epileptic children treated with phenytoin compared to normal controls.
- A significant negative correlation was found between serum IgA levels and the duration of phenytoin treatment.
- Eight patients exhibited IgA deficiency.
- T lymphocyte subpopulations did not differ significantly between patients and controls.
Conclusions:
- Phenytoin treatment in children and adolescents may be associated with reduced IgA and IgM levels.
- The duration of phenytoin therapy appears to influence serum IgA levels.
- Further research is warranted to elucidate the mechanisms and clinical implications of these immunological changes.
Abstract:
In a longitudinal study we have evaluated several immunological parameters in thirty three epileptic children and adolescents 4 to 14 years old treated with phenytoin, and matched normal controls. The patients had significantly lower levels than normal controls of IgA (153 +/- 89 vs 236 +/- 128 mg/dL p less than 0.001) and IgM (155 +/- 58 vs 217 +/- 105 mg/dL p less than 0.01). The decrease in serum IgA levels correlated with the length of treatment (r = 0.44, p less than 0.03). Eight of the patients had IgA deficiency. In 7 of these children, T lymphocytes subpopulations were determined. The results did not differ significantly from the matched controls.